Most pharmaceutical compounds are not sufficiently deactivated at wastewater treatment facilities (WWTFs) (utilizing biological treatment, electrocoagulation, coagulation and membrane filtration processes) and eventually end up being discharged into the environment. These pharmaceuticals threaten aquatic ecosystems, contribute to bacterial drug resistance, and eventually return to human drinking water supplies.
One recent study of biologically active pollutants in Puget Sound estuaries found forty-two (42) compounds in the tissue of whole-body juvenile Chinook salmon, including high concentrations of amphetamines (ADDERALL® and other drugs for ADD and recreational abuse), fluoxetine (PROZAC® antidepressant), and sertraline (ZOLOFT® anti-depressant). Most pharmaceutical compounds are typically non-lethal to organisms, but they do change behavior. The impact of this is hard to estimate (or even fully understand), but the effects are certain to ripple through the ecosystem placing additional stress on already fragile populations. The problem is big and growing, and it is both scientifically and economically challenging to treat large volumes of WWTP effluent that are polluted with dilute concentrations of 1,000+ chemically different compounds.
Advanced oxidation processes (AOPs) are an attractive technology to address this growing problem because of their ability to degrade most organic species via the in-situ generation of oxidizing species (e.g., OH, H2O2, O2, O3, HOCl), which can be generated through photochemical or electrochemical means. The dominant route for pharmaceutical excretion is in urine; therefore, decentralized AOPs, which treat this concentrated source of pharmaceuticals before it is diluted with other wastewater streams, would allow for much higher efficiency toward pharmaceutical degradation. Multiple studies have examined pharmaceutical degradation using AOPs for over a decade, but recent works have highlighted that toxic byproducts (TBPs) (e.g., chlorate, perchlorate, haloacetic acids, aliphatic halides species, haloacetonitriles, and haloacetamides) formed during AOPs compromise the quality of the treated effluent. These TBPs are mostly chlorinated species; however, brominated and iodinated species may be present at much lower concentrations but with higher toxicity. Of the toxic byproducts, ClO4− is perhaps the biggest problem due to its exceptionally high stability and low toxicity threshold. Thus, there is a need to develop novel AOPs that have high efficiency toward pharmaceutical reduction to prevent or mitigate ClO4− formation.
Multiple studies have examined the electrochemical oxidation of simulated fresh urine, stored urine, or simulated stored urine. Though the details used in these studies vary significantly, there are examples where the concentrations of generated ClO4− for roughly equivalent oxidation treatments are vastly different. For a normalized charge passed of 30 Ahrs/L, two studies report 100% oxidation of chloride to ClO4−, while another reports ClO4− below the detection limit. One big difference between these studies is the composition of the matrix. Urine has a high concentration of nitrogen of about 10 g/L, which is bound in the form of urea. However, natural abundant bacterial urease hydrolyzes urea to form ammonium, bicarbonate, and OH−. This reaction happens rapidly, with one study finding that urea is nearly completely hydrolyzed within 5 hours of storage in a pipe. The dissolved ammonium is in equilibrium with dissolved ammonia, which is volatile and will evaporate over time if exposed to open air.
In separate literature, electrochemical reduction of has been demonstrated for various toxic byproducts, including aliphatic chlorides, haloacetic acids, nitrosamines, ClO3−, and ClO4−. Generally, the electrochemical reduction of these species is favored at low pH. Of all of these TBPs ClO4− has the slowest reduction rate, because of its exceptionally large reduction activation barrier of 120 kJ/mole. A recent review on the electrocatalytic reduction of ClO4− identified three possible mechanisms for the electrocatalytic reduction of ClO4−: (1) electrocatalysis, (2) hydrodeoxygenation, and (3) multivalent titanium ion reduction.
Despite the advances in the electrochemical degradation of organic compounds such as pharmaceuticals, a need exists for improved methods that not only effectively degrade these compounds but further limit the production of toxic byproducts. The present seeks to fulfill this need and provides further related advantages.
In one aspect of the invention, methods for electrochemically oxidizing organic compounds are provided.
In one embodiment, the method comprises:
(a) contacting an aqueous solution comprising organic compounds with a first anode and electrochemically oxidizing at least a portion of the organic compounds to provide a first aqueous solution comprising oxidation products; and
(b) contacting the first aqueous solution comprising oxidation products with a first cathode and electrochemically reducing at least a portion of the oxidation products to provide a first aqueous solution comprising reduced products and residual oxidizable organic compounds.
In certain of these embodiments, the methods further comprise contacting the first aqueous solution comprising reduced products and residual oxidizable organic compounds with a second anode and electrochemically oxidizing at least a portion of the residual oxidizable organic compounds to provide a second aqueous solution comprising oxidation products. In certain embodiments, the second anode is the same as (e.g., recycle process) or different from (e.g., multiple anode configuration) from the first anode.
In certain of these embodiments, the methods further comprise contacting the second aqueous solution comprising oxidation products with a second cathode and electrochemically reducing at least a portion of the oxidation products to provide a third aqueous solution comprising reduced products and residual oxidizable organic compounds. In certain embodiments, the second cathode is the same as (e.g., recycle process) or different from (e.g., multiple cathode configuration) the first cathode.
In another aspect, the invention provides systems and devices having a variety of electrode configurations effective to carry out the methods described herein.
The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings.
The present invention provides systems and methods for in-situ electrochemical reduction of toxic byproducts (TBPs) after the application of an advanced oxidation processes (AOP).
The present invention provides two important advances in field of advanced oxidation processes for wastewater treatment. First, the present invention reveals the beneficial effects of high ammonia content to prevent the generation of perchlorate and chlorate. In certain embodiments, the invention provides systems and methods for immediately treating contaminated urine at the source of generation. Second, in certain embodiments, the invention provides electrochemical systems and methods based on divided cells using inexpensive glass frits. As a result, acidification of the oxidized matrix can be advantageously used for a subsequent reduction treatment to reduce toxic byproducts.
Disclosed herein is an electrochemical systems and methods to sequentially and/or repeatedly oxidize and reduce liquid waste streams that contain molecular pollutants or organisms. The process of organic compound degradation can be thought of as “molecular shredding” to chop-up molecules and reduce their biological activity without creating significant concentrations of toxic byproducts.
In one embodiment, the invention provides system and methods for point-source treatment of pharmaceutical compounds in human urine, before the massive dilution that occurs in-route to wastewater treatment facilities (WWTFs). Devices utilizing the technology are inexpensive, energy efficient, easy to operate, avoid the use of corrosive additives, and do not create significant toxic byproducts. This enables implementation in homes, hospitals, or other locations without the need for specialized assistance for operation or maintenance. The application of the technology extends beyond the destruction of pharmaceutical compounds in urine. Further applications include: (1) treatment of WWTF effluent to remove pharmaceuticals as a polishing step; (2) treatment of cargo-ship ballast water in-situ during its journey to disinfect the water and prevent the spread of invasive organisms across the globe; (3) destruction of polychlorinated biphenyls (PCBs) in groundwater; (4) treatment of drinking water at the time and point of use; and (5) de-toxification of an organic contaminant from an industrial or commercial site before discharge into the environment or discharge into the sewer.
Electrochemical Methods
In one aspect of the invention, methods for electrochemically oxidizing organic compounds are provided.
In one embodiment, the method comprises:
(a) contacting (e.g., flowing) an aqueous solution comprising organic compounds with a first anode and electrochemically oxidizing at least a portion of the organic compounds to provide a first aqueous solution comprising oxidation products; and
(b) contacting (e.g., flowing) the first aqueous solution comprising oxidation products with a first cathode and electrochemically reducing at least a portion of the oxidation products to provide a first aqueous solution comprising reduced products and residual oxidizable organic compounds.
The oxidation products of the methods of the invention include the oxidized organic compounds (e.g., oxidatively degraded organic compounds, such as shredded pharmaceuticals) and chlorine-based oxidation products. The oxidation products include inorganic oxidation products, e.g., Cl− oxidation products.
The reduced products of the methods of the invention include the reduction products derived from the chlorine-based oxidation products (e.g., to prevent formation of TBP, such as perchlorate and trichloromethane). In certain aqueous media (e.g., urine) a main mechanism of action is oxidation of chloride (Cl−), which forms active chlorine species that then oxidize organic compounds in solution homogeneously (as opposed to heterogeneous oxidation on the electrode surface).
In the methods of the invention, the aqueous solutions are contacted with either the anode or cathode. In certain embodiments, the aqueous solutions flow from one electrode to the next. See, for example,
In the methods of the invention, first aqueous solution comprising oxidation products also includes organic compounds that have not been oxidized (i.e., residual oxidizable organic compounds). That is, in the methods only a portion of the organic compounds are oxidized in step (a) (i.e., first contact with the anode), and that in order to fully degrade (or shred) the organic compounds repetition is required to achieve the desired levels of residual organic compounds (e.g., recycle the solution of partially degraded organic compounds to the first anode or conduct (e.g., flow) the solution of partially degraded organic compounds to a second anode). Representative methods of recycling to the first anode are shown in
Likewise, the first aqueous solution comprising reduced products—the product of step (b)—also includes organic compounds that have not been oxidized (i.e., residual oxidizable organic compounds)—and further electrochemical oxidative action is required to lower ultimate level of organic compounds in effluent.
As noted above, in certain embodiments, the solution of partially degraded organic compounds is subject to a second cycle of oxidation/reduction.
In certain of these embodiments, the methods further comprise contacting (e.g., flowing) the first aqueous solution comprising reduced products and residual oxidizable organic compounds with a second anode and electrochemically oxidizing at least a portion of the residual oxidizable organic compounds to provide a second aqueous solution comprising oxidation products. In certain embodiments, the second anode is the same as (e.g., recycle process) or different from (e.g., multiple anode configuration) from the first anode.
In certain of these embodiments, the methods further comprise contacting (e.g., flowing) the second aqueous solution comprising oxidation products with a second cathode and electrochemically reducing at least a portion of the oxidation products to provide a third aqueous solution comprising reduced products and residual oxidizable organic compounds. In certain embodiments, the second cathode is the same as (e.g., recycle process) or different from (e.g., multiple cathode configuration) the first cathode.
In another embodiment, the invention provides a method for electrochemically oxidizing organic compounds as schematically shown in
(a) electrochemically oxidizing at least a portion of organic compounds in an aqueous solution in a first divided cell having a first anode compartment separated from a first cathode compartment by a porous membrane to provide a first aqueous solution comprising oxidation products;
(b) conducting the first aqueous solution comprising oxidation products to a second divided cell having a second anode compartment separated from a second cathode compartment by a porous membrane; and
(c) electrochemically reducing at least a portion of the oxidation products in the second divided cell to provide an aqueous solution comprising reduced products.
In certain of these embodiments, the aqueous solution of reduced products comprises residual oxidizable organic compounds and is conducted (e.g., recycled) to the first divided cell and at least a portion of the residual oxidizable organic compounds are electrochemically oxidized to provide a second aqueous solution comprising oxidation products.
In certain of these embodiments, the second aqueous solution comprising oxidation products and is conducted to the second divided cell and at least a portion of the oxidation products are electrochemically reduced to provide a second aqueous solution comprising reduced products.
It will be appreciated that the methods do not require the use of a porous membrane (e.g., a divided cell) is not required, but may be useful in order to swing the pH by H+ and OH− generation on the anode and cathode, respectively.
In certain embodiments, the first aqueous solution comprising oxidation products from the anode compartment of the first divided cell is conducted to the cathode compartment of the second divided cell and the first aqueous solution comprising oxidation products from the cathode compartment of the first divided cell is conducted to the anode compartment of the second divided cell. In certain of these embodiments, the first aqueous solution comprising oxidation products conducted to the cathode compartment of the second divided cell and the first aqueous solution comprising oxidation products conducted to the anode compartment of the second divided cell are reduced to provide a second aqueous solution comprising reduced products. In certain of these embodiments, the second aqueous solution comprising reduced products and residual oxidizable organic compounds are conducted from the cathode and anode compartments of the second divided cell to the first divided cell for further oxidation. In certain embodiments, hydrogen generated in the cathode compartment of the first cell is conducted to the second cell to enhance reduction.
In another embodiment, the invention provides a method for electrochemically oxidizing organic compounds as schematically shown in
In a further embodiment, the invention provides a method for electrochemically oxidizing organic compounds as schematically shown in
Additional representative systems for carrying out the methods of the invention are schematically illustrated in
In certain embodiments, the invention provides devices having one planar anode and one planar cathode as shown schematically in
Referring to
(a) contacting (e.g., flowing) an aqueous solution comprising organic compounds with a planar anode and electrochemically oxidizing at least a portion of the organic compounds to provide an aqueous solution comprising oxidation products; and
(b) contacting (e.g., flowing) the aqueous solution comprising oxidation products with a planar cathode and electrochemically reducing at least a portion of the oxidation products to provide an aqueous solution comprising reduced products and residual oxidizable organic compounds,
wherein the planar anode is positioned on a first surface, the planar cathode is positioned on a second surface, and the first surface is parallel to and separated from the second surfaces to define a channel between the planar anode and planar cathode, wherein the channel provides liquid communication of the aqueous solution comprising oxidation products with the planar cathode and liquid communication of the aqueous solution comprising reduced products and residual oxidizable organic compounds with the planar anode.
In certain embodiments, the invention provides devices having two planar anodes and two planar cathodes in an alternating configuration as shown schematically in
Referring to
(a) contacting (e.g., flowing) an aqueous solution comprising organic compounds with a first planar anode and electrochemically oxidizing at least a portion of the organic compounds to provide a first aqueous solution comprising oxidation products;
(b) contacting (e.g., flowing) the first aqueous solution comprising oxidation products with a first planar cathode and electrochemically reducing at least a portion of the oxidation products to provide a first aqueous solution comprising reduced products and residual oxidizable organic compounds;
(c) contacting (e.g., flowing) the first aqueous solution comprising reduced products and residual oxidizable organic compounds with a second planar anode and electrochemically oxidizing at least a portion of the organic compounds to provide a second aqueous solution comprising oxidation products; and
(d) contacting (e.g., flowing) the second aqueous solution comprising oxidation products with a second planar cathode and electrochemically reducing at least a portion of the oxidation products to provide a second aqueous solution comprising reduced products and residual oxidizable organic compounds,
wherein the first planar anode and second planar cathode are positioned on a first surface, the first planar cathode and second planar anode are positioned on a second surface, and the first surface is parallel to and separated from the second surface to define a channel between the first planar anode and the second planar cathode on the first surface and the first planar cathode and second planar anode on the second surface, wherein the channel provides liquid communication between the anodes and cathodes.
In certain embodiments, the invention provides devices having a single surface with interdigitated electrodes and or two opposing surfaces with interdigitated electrodes. Representative devices having interdigitated anodes and cathodes in an alternating configuration shown schematically in
Referring to
(a) introducing an aqueous solution comprising organic compounds into an electrochemical cell, wherein the cell comprises:
(i) one or more anodes for electrochemically oxidizing at least a portion of the organic compounds to provide oxidation products; and
(ii) one or more cathodes for electrochemically reducing at least a portion of the oxidation products, wherein the one or more anodes and one or more cathodes are alternately positioned on a surface to provide an array of interdigitated anodes and cathodes; and
(b) conducting the aqueous solution through the cell to provide an aqueous solution comprising reduced products and residual oxidizable organic compounds.
Referring to
(a) introducing an aqueous solution comprising organic compounds into an electrochemical cell, wherein the cell comprises:
(i) a first surface comprising
one or more anodes for electrochemically oxidizing at least a portion of the organic compounds to provide oxidation products, and
one or more cathodes for electrochemically reducing at least a portion of the oxidation products,
wherein the one or more anodes and one or more cathodes are alternately positioned on the surface to provide an array of interdigitated anodes and cathodes; and
(ii) a second surface comprising
one or more cathodes for electrochemically reducing at least a portion of the oxidation products, and
one or more anodes for electrochemically oxidizing at least a portion of the organic compounds to provide oxidation products;
wherein the one or more anodes on the first surface and the one or more cathodes on the second surface are alternately positioned on each surface to provide an array of interdigitated anodes and cathodes,
wherein the first surface is parallel to and separated from the second surface to define a channel between the interdigitated anodes and cathodes on the first surface and the interdigitated anodes and cathodes on the second surface, wherein the channel provides liquid communication between the anodes and cathodes; and
(b) conducting the aqueous solution through the cell to provide an aqueous solution comprising reduced products and residual oxidizable organic compounds.
In the methods described herein, the anode generates oxidants. Representative oxidants generated by the anode include surface bound hydroxyl radicals, dissolved hydroxyl radicals, chlorine radicals, HOCl and OCl−, and carbonate radicals. In certain embodiments, the anode is a metal oxide or a combination of metal oxides (e.g., doped metal oxides, doped tin oxide, fluorine-doped tin oxide). In certain embodiments, the anode or the surface of the anode comprises carbon (e.g., amorphous carbon, graphite, graphene, graphene oxide, diamond, doped carbon, boron-doped diamond). In certain embodiments, the anode is a boron-doped diamond anode. In other embodiments, the anode is an iridium dioxide (IrO2) anode.
In the methods described herein, the cathode is effective in reducing chlorate, perchlorate, haloacetic acids, halomethanes, haloethanes, and nitrosamines. In certain embodiments, the cathode is a metal or a combination of metals. Representative metals include iron, platinum, molybdenum, titanium, nickel, silver, and copper. Representative combinations of metals include steel and stainless steel. In certain embodiments, the cathode is a carbon cathode. Representative carbon cathodes comprise amorphous carbon, graphite, graphene, graphene oxide, diamond, doped carbon, and boron-doped diamond.
In the methods described herein, the organic compounds that are effectively treated are organic compounds that are capable being degraded by electrochemical oxidization. Representative organic compounds capable being degraded by electrochemical oxidization include pharmaceutical compounds. Representative degradable pharmaceutical compounds include fluoxetine, sertraline, metformin, carbamazepine, ibuprofen, sulfamethoxazole, and cyclophosphamide. In certain embodiments, the organic compounds are polychlorinated biphenyls.
In certain embodiments, the aqueous solution subject to electrochemical oxidation further comprises a microorganism, which is effectively degraded by the methods described herein. Representative microorganisms include Cholera (Vibrio cholerae), Cladoceran Water Flea (Cercopagis pengoi), Mitten Crab (Eriocheir sinensis), toxic algae, Round Goby (Neogobius melanostomus), North American Comb Jelly (Mnemiopsis leidyi), North Pacific Seastar (Asterias amurensis), Zebra Mussel (Dreissena polymorpha), Asian Kelp (Undaria pinnatifida), and European Green Crab (Carcinus maenas).
In certain embodiments, the aqueous solution comprising organic compounds is ship ballast water.
In other embodiments, the methods described herein are useful as point-source treatment pre-dilution in wastewater treatment facilities. In certain of these embodiments, the aqueous solution comprising organic compounds is human urine and the organic compounds to be electrochemically oxidatively degraded are pharmaceuticals.
Electrochemical Systems
Representative systems (i.e., electrode configurations) for carrying out the methods of the invention are schematically illustrated in
In certain embodiments, the systems of the invention include planar arrangements of electrodes (anodes and cathodes).
In certain embodiments, the invention provides devices having two planar anodes and two planar cathodes in an alternating configuration as shown schematically in
Referring to
In certain embodiments, the invention provides systems having a single surface with interdigitated electrodes and or two opposing surfaces with interdigitated electrodes. Representative devices having interdigitated anodes and cathodes in an alternating configuration shown schematically in
Referring to
The following is a description of representative systems and methods of the invention.
The Advantages of Decentralized Treatment of Urine
Point-source treatment of fresh urine has multiple advantages: (1) chemical oxygen demand (COD), (2) conductivity, (3) nitrogen content. Average human urine production is 1.3 Lp−1d−1, while average domestic wastewater discharge is 148 Lp−1d−1. The dilution of urine with these other waste streams not only decreases the absolute concentration of pharmaceuticals, but it also decreases their relative concentration compared to the total concentration of organics in the solution. This is due to mixing with other organics such as cooking oils, and detergents. This domestic wastewater may be further diluted by other waste streams containing other organics before reaching a WWTF (e.g., industrial wastewater, urban runoff). One way to quantify this is to compare the COD from pharmaceuticals vs. the COD of the matrix on a per person per day as shown in Table 1.
In Table 1, the calculations assumed an electricity rate of 0.15 $/kWhr, a pharmaceutical concentration of 10 mM (which is estimated to require 100 mM of oxygen for COD calculations), an applied voltage of 6 V, a faradaic efficiency toward reactive oxidant generation of 15%, and assumes 50% of oxidants react to reduce COD. Matrix composition taken from Larsen, Source Separation and Decentralization for Wastewater Management. Water Intell. Online 12, (2013).
In a scenario where pharmaceuticals are the only source of COD in the matrix, it would take only 50.07 to oxidize all pharmaceuticals. This cost is moderately increased to $0.50 when all the COD of the urine matrix is included and is substantially increased to $3.55 when COD from all domestic wastewater is included. The CODpharm/CODtotal decreases from 14% to 2% once the urine stream is mixed with other domestic wastewater streams. The calculations presented in Table 1 represent a lower bound on the daily cost for electrochemical treatment of these systems, particularly for the larger treatment volumes. Diluted fresh urine has substantially larger volume and lower conductivity, which drastically increases the cost required to electrochemically remediate pharmaceuticals due to larger electrode requirements, longer treatment times, and high solution resistivity.
Another major benefit of treating pharmaceutical containing urine at its source is the high urea content in urine, which inhibits the formation of chlorate and perchlorate. To examine how dissolved nitrogen concentration affects the formation of perchlorate, a series of oxidations were performed on a BDD electrode as shown in
The Oxidation of Pharmaceutical in a Simple Urine Matrix
In contrast to BDD, the CVs of IrO2 in
In order to examine the potential of point-source treatment of pharmaceuticals in fresh-urine matrices, a series of experiments were performed with BDD and IrO2 anodes. Oxidation experiments were performed on both of these electrodes with one of two pharmaceuticals, sulfamethoxazole (SMX) and cyclophosphamide (CP), each in a non-divided and divided cell configuration. CP and SMX were chosen as test compounds because of their major differences in reactivity toward active chlorine species. SMX has a relatively high bimolecular rate constant with HOCl of 103 M−1s−1, while we measured CP to have an exceptionally low bimolecular rate constant of about 10−6 M−1s−1. A schematic of the non-divided and divided cell configurations for oxidation are shown in
The rate of pharmaceutical degradation and the rate of toxic byproduct generation were compared between every combination of pharmaceutical, anode, and cell configuration as shown in
The Reduction of TBPs in an Acidified Urine Matrix
In order to demonstrate the potential of a reduction treatment after an advanced oxidation process, a series of reduction experiments were performed on platinum (Pt), molybdenum (Mo), and titanium (Ti) cathodes.
In order to test the optimum reduction conditions for the oxidized urine matrix, a pH 2 solution with 5 ppm of ClO4 and 30 ppm of ClO3− was reduced on Pt, Mo, and Ti cathodes. In all of these experiments, a potentiostatic voltage was maintained (at −400, −550, −700, or −850 mV) for 3 hours in a divided cell (as depicted in
Alternation of Oxidation and Reduction
In order to demonstrate the potential of a subsequent reduction treatments in AOPs to remediate TBPs, we performed a reduction treatment on acidified, oxidized urine matrices as shown in
As also shown in
While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.
This application claims the benefit of U.S. Application No. 62/899,583, filed Sep. 12, 2019, expressly incorporated herein by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/050433 | 9/11/2020 | WO |
Number | Date | Country | |
---|---|---|---|
62899583 | Sep 2019 | US |